Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Rapid HTAs of four medical devices released in Tuscany

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 6700 of March 27, 2024, Tuscany Regional Healthcare published three new assessments and one re-assessment of medical devices in the cardiovascular, men’s health, nephrology and urology, and surgical procedures areas.

The assessed technologies are provided below:

  • Tricuspid valve reconstruction system Cardioband tricuspid system by Edwards Lifesciences for patients with severe tricuspid valve insufficiency caused by annular dilatation who remain symptomatic on medical therapy and are at high risk for surgery (update);
  • Prostatic urethral lifting system UroLift by Neotract for young patients suffering from benign prostatic hyperplasia (BPH) and retrograde ejaculation who need to preserve fertility;
  • Urethral drug coated (paclitaxel) balloon catheter OPTILUME by Urotronic for patients with recurrent urethral stricture resistant to surgical urethrotomy treatment candidates for urethroplasty treatment;
  • Sterile silicone breast prostheses Motiva Implants Ergonomix Round SmoothSilk/SilkSurface by Establishment Labs for female patients requiring breast reconstruction, patients - candidates for unilateral mastectomy with particular conformation of the breasts (medium-large volume, medium-high ptosis), female patients aged > 18 years requiring breast augmentation.

See the regional decree and all assessments in Italian here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.